RaQualia Pharma (TSE:4579) Institutional Ownership: 0.14% (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4579 RaQualia Pharma Inc TSE:4579
60 GF Score
Price 円488.00
GF Value 円311.16
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is RaQualia Pharma Institutional Ownership?

RaQualia Pharma TSE:4579 +1.24% 60 Institutional Ownership is 0.14% as of Aug. 05, 2026. GuruFocus rates TSE:4579 with a GF Score™ of 60/100 and a GF Value™ of 円311.16 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, RaQualia Pharma's institutional ownership is 0.14%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, RaQualia Pharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, RaQualia Pharma's Float Percentage Of Total Shares Outstanding is 0.00%.

RaQualia Pharma Institutional Ownership Historical Data

* Premium members only.

The historical data trend for RaQualia Pharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma Institutional Ownership Chart

RaQualia Pharma Historical Data

The historical data trend for RaQualia Pharma can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 0.27 0.24 0.23 0.21 0.17 0.17 0.15 0.14 0.14 0.14
TSE:4579
60GF Score
RaQualia Pharma Inc TSE:4579
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaQualia Pharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.14% mean?
RaQualia Pharma (TSE:4579) has a Institutional Ownership of 0.14% as of Aug. 05, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on RaQualia Pharma and its competitors.
Is RaQualia Pharma's Institutional Ownership too high?
RaQualia Pharma's current Institutional Ownership is 0.14%. Overall, RaQualia Pharma has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Institutional Ownership compare to VRTX and REGN?
RaQualia Pharma's Institutional Ownership of 0.14% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on RaQualia Pharma and its competitors. RaQualia Pharma's current Institutional Ownership is 0.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Overvalued. The stock's GF Value™ is 円311.16, compared to a current price of 円488.00 — trading 56.8% above its estimated fair value. The current Institutional Ownership is 0.14%. RaQualia Pharma's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Institutional Ownership is 0.14% as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be overvalued. The current stock price of 円488.00 is trading 56.8% above its estimated GF Value™ of 円311.16. GuruFocus considers RaQualia Pharma to be Significantly Overvalued.

Key valuation signals for TSE:4579:

  • Institutional Ownership: 0.14%
  • GF Value™: 円311.16 vs. price of 円488.00 (56.8% above fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RaQualia Pharma Business Description

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
60GF Score

Get the complete analysis for TSE:4579

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円488.00
Price
円311.16
GF Value